Propargyl-PEG2-beta-D-glucose

Cat. No.: HY-141131

CAS No.: 2353409-73-9

Molecular Formula: $C_{13}H_{22}O_8$

Molecular Weight: 306.31

Target: PROTAC Linkers

Pathway: PROTAC

Storage:

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (326.47 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	3.2647 mL	16.3233 mL	32.6467 mL
	5 mM	0.6529 mL	3.2647 mL	6.5293 mL
	10 mM	0.3265 mL	1.6323 mL	3.2647 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 10 mg/mL (32.65 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% saline
   Solubility: ≥ 10 mg/mL (32.65 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: 2.17 mg/mL (7.08 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

Propargyl-PEG2-beta-D-glucose is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].

IC_{50} & Target

PEGs

In Vitro

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA